Recently identified peptides involved in the regulation of body weight.

Abstract:

:The application of molecular and genetic techniques to the study of body weight regulation have produced exciting new insights into the physiological systems governing energy expenditure, appetite, and metabolic signaling. A number of new peptides have been identified that play important roles in these regulatory systems. These include the hormone leptin, the short and long forms of the leptin receptor, uncoupling proteins, agouti protein, melanocortin receptor isoforms, melanin-concentrating hormone, and the proteins responsible for tub and fat, two monogenic mouse models of obesity. This article reviews some of the new insights gained from studies of these peptides. Although much of this new knowledge has come from studies of obesity, there may be implications for the clinical syndromes associated with weight loss. As more is learned about these systems, potential new targets for therapeutic intervention will likely become evident. These interventions may develop first as obesity treatments, but investigators and clinicians involved in the care of cachectic patients should follow these scientific developments as well.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Bessesen DH,Faggioni R

subject

Has Abstract

pub_date

1998-04-01 00:00:00

pages

28-32

issue

2 Suppl 6

eissn

0093-7754

issn

1532-8708

journal_volume

25

pub_type

杂志文章,评审
  • Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

    abstract::We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Bruntsch U,Drechsler S,Eggert J,Gosse H,Ukena D,Imhoff W,Faerber L

    更新日期:1994-10-01 00:00:00

  • High-dose megestrol acetate in the treatment of advanced breast cancer.

    abstract::A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Tchekmedyian NS,Tait N,Abrams J,Aisner J

    更新日期:1988-04-01 00:00:00

  • Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.

    abstract::Long-term survival is occasionally observed in patients with neoplastic meningitis (NM) accompanying breast cancer (13% one-year and 6% 2-year survival), melanoma, and lymphoma, but in general the survival of most patients is short and averages only 3 to 4 months. The incidence of NM appears to be increasing, in part ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.04.016

    authors: Jaeckle KA

    更新日期:2006-06-01 00:00:00

  • New antimetabolites in the treatment of human malignancies.

    abstract::Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cheson BD

    更新日期:1992-12-01 00:00:00

  • Palliative radiation therapy.

    abstract::Radiation is an effective modality to aid in symptom management of patients with metastatic disease. The type and duration of treatment depends on the Karnofsky performance status (KPS) of the patient and type and status of the cancer. Abbreviated treatment regimens may be favored in this patient population. They prov...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.11.013

    authors: Konski A,Feigenberg S,Chow E

    更新日期:2005-04-01 00:00:00

  • Diagnosis and treatment of uveal melanoma.

    abstract::Most malignant melanomas in the ocular region arise in the uveal tract (iris, ciliary body, and choroid). Uveal melanoma generally has characteristic clinical features and the diagnosis can usually be made by an experienced ophthalmologist using slit lamp biomicroscopy or indirect ophthalmoscopy. Ancillary studies suc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Shields JA,Shields CL,De Potter P,Singh AD

    更新日期:1996-12-01 00:00:00

  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • Novel radiation therapy approaches for breast cancer treatment.

    abstract::The role of radiation therapy in the management of breast cancer continues to evolve. For patients with early stage breast cancer, hypofractionated whole breast irradiation following breast conserving surgery now represents the standard of care based on randomized data with long-term efficacy and toxicity outcomes. Pa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.05.003

    authors: Shah C,Bauer-Nilsen K,McNulty RH,Vicini F

    更新日期:2020-08-01 00:00:00

  • Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.

    abstract::Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.009

    authors: Chao KS,Ozyigit G,Thorsdad WL

    更新日期:2003-12-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

    abstract::Adjuvant chemotherapy has a real but modest impact on the disease-free and overall survival of patients with breast cancer. Recent attempts to improve its effectiveness have focused on dose intensity and new agents. Sequential therapy maximized dose intensity while limiting overlapping toxicity. Sequential therapy usi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hudis C,Seidman A,Raptis G,Fennelly D,Gilewski T,Baselga J,Theodoulou M,Sklarin N,Moynahan M,Surbone A,Currie V,Lebwohl D,Uhlenhopp M,Crown J,Norton L

    更新日期:1996-02-01 00:00:00

  • New approaches to treating malignances with stem cell transplantation.

    abstract::Stem cell transplantation has been successfully used to treat a wide variety of hematologic malignancies. New and exciting strategies being developed for use in conjunction with transplant will be useful in overcoming tumor resistance. It is now clear that a significant part of the antitumor effect of allogeneic stem ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Margolis J,Borrello I,Flinn IW

    更新日期:2000-10-01 00:00:00

  • Whole cell vaccines--past progress and future strategies.

    abstract::Cancer vaccines have shown success in curing tumors in preclinical models. Accumulating evidence also supports their ability to induce immune responses in patients. In many cases, these responses correlate with improved clinical outcomes. However, cancer vaccines have not yet demonstrated their true potential in clini...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.02.007

    authors: Keenan BP,Jaffee EM

    更新日期:2012-06-01 00:00:00

  • Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

    abstract::Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Synold TW,Tetef ML,Doroshow JH

    更新日期:1998-08-01 00:00:00

  • Training and mentoring surgeons in lymphatic mapping.

    abstract::Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.005

    authors: Wilke LG

    更新日期:2004-06-01 00:00:00

  • Paclitaxel pharmacokinetics and pharmacodynamics.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kearns CM,Gianni L,Egorin MJ

    更新日期:1995-06-01 00:00:00

  • Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.

    abstract::In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

    更新日期:1997-08-01 00:00:00

  • Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

    abstract::Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

    更新日期:1993-10-01 00:00:00

  • Acute promyelocytic leukemia: recent advances in diagnosis and management.

    abstract::Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RARalpha), and leading to a blockage in the differentiation of the granulocytic cells. The accumulation of the promyelocytic blasts in the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2008.04.010

    authors: Lo-Coco F,Ammatuna E,Montesinos P,Sanz MA

    更新日期:2008-08-01 00:00:00

  • Cardiac testing to manage cardiovascular risk in cancer patients.

    abstract::Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.01.003

    authors: Davis M,Witteles RM

    更新日期:2013-04-01 00:00:00

  • Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials.

    abstract::The potential benefits of docetaxel (Taxotere; Aventis, Antony, France) to patients with previously-treated non-small cell lung cancer have been evaluated in two prospective randomized phase III trials. In one study, patients with stage IIIB/IV non-small cell lung cancer who had failed previous cisplatin-based chemoth...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Shepherd FA,Fossella FV,Lynch T,Armand JP,Rigas JR,Kris MG

    更新日期:2001-02-01 00:00:00

  • Oligodendroglial tumors.

    abstract::Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. I...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.06.009

    authors: Jaeckle KA

    更新日期:2014-08-01 00:00:00

  • Combination paclitaxel and platinum in the treatment of lung cancer: US experience.

    abstract::Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1996-12-01 00:00:00

  • Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

    abstract::Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Holmes FA

    更新日期:1996-10-01 00:00:00

  • Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

    abstract::Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1053/j.seminoncol.2017.01.001

    authors: Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

    更新日期:2017-02-01 00:00:00

  • Mechanism of action of trastuzumab and scientific update.

    abstract::The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90276-3

    authors: Baselga J,Albanell J,Molina MA,Arribas J

    更新日期:2001-10-01 00:00:00

  • The root causes of pharmacodynamic assay failure.

    abstract::Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.06.006

    authors: Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

    更新日期:2016-08-01 00:00:00

  • Involvement of platelet-derived microparticles in tumor progression and thrombosis.

    abstract::Platelet-derived microparticles (PMPs) represent the most abundant microparticle (MP) subtype. Their presence reflects platelet activity, physiopathology, and the thrombotic state of cancer patients. The quantity and composition of PMPs strictly depends on the way MPs were generated. Because platelets play a key role ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.04.010

    authors: Mezouar S,Mege D,Darbousset R,Farge D,Debourdeau P,Dignat-George F,Panicot-Dubois L,Dubois C

    更新日期:2014-06-01 00:00:00

  • Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.

    abstract::Cisplatin/etoposide/bleomycin (DEB) was given as an outpatient regimen in a novel weekly schedule to 27 patients with recurrent and/or widely metastatic cancer of the head and neck region. Six of these patients also received mitomycin (DEB/M) when their disease failed to respond after at least three weekly DEB doses. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Osoba D,Band PR,Connors JM,Goldie JH,Knowling MA,Fetherstonhaugh EM

    更新日期:1992-04-01 00:00:00

  • Failure of senescence in the dysplasia-melanoma sequence: demonstration using a tissue microarray and a revised paradigm for melanoma.

    abstract::In order to correlate changes in morphology to changes in molecular attributes, we constructed a tissue microarray of thin and thick melanomas selected to represent progression from dysplasia to early and advanced melanoma. Hematoxylin and eosin (H&E) staining and immunohistology with antibodies to cyclin D1, p16, Ki6...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.09.014

    authors: Tuthill RJ,Reed RJ

    更新日期:2007-12-01 00:00:00